Incregen Therapeutics Advances First-in-Class GIP Ligand Antagonist INC-118 into IND-Enabling Development to Address Long-Term Obesity Management INC-118 directly antagonizes the circulating Glucose ...
ASPIRO is the first multi-patient, multi-center clinical trial of an autologous cell therapy for Parkinson's disease. It is evaluating safety, tolerability, and preliminary efficacy of ANPD001 in ...
Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 –-- ...
InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa ...
Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens Designed to Explore Maintenance Dosing Regimens Following Initial Weight ...
Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 - -- Expects to initiate global Phase 1/2 MAD clinical study ...
Today, American Global Strategies LLC announced that Chad F. Wolf, the former Acting Secretary of Homeland Security under President Donald J. Trump, has joined the firm as a Vice ...
Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens Designed to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 ...
The Wasp-class amphibious assault ship Medical department certified Role 2 medical capable one year early, Dec. 1, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback